AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN, on the one hand, XENCOR, INC., AND, on the other hand, GENENTECH, INC. AND F. HOFFMANN-LA ROCHE LTD, EFFECTIVE AS OF JUNE 1, 2024Collaboration and License Agreement • February 29th, 2024 • Xencor Inc • Pharmaceutical preparations • California
On November ___, 2023, the Company entered into an Amended and Restated Collaboration and License Agreement (the “New Collaboration Agreement”) with Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and F. Hoffmann-La Roche Ltd, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). The New Collaboration Agreement is effective as of June 1, 2024 (the “Effective Date”) and, as of that date, will replace the current Collaboration and License Agreement between the Company and Roche which was entered into on February 4, 2019 (the “Original Collaboration Agreement”). The Original Collaboration Agreement will remain effective for the period between February 4, 2019 and the Effective Date.
